A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

August 20, 2025 updated by: BioRestorative Therapies

A Phase 2, Double-Blind, Controlled, Randomized Study to Evaluate the Safety and Preliminary Efficacy of a Single Dose Intradiscal Injection of BRTX-100 for Patients With Chronic Lumbar Disc Disease (cLDD)

This is a double-blind, controlled, randomized study with blinded assessments using a single dose. Subjects that have a current diagnosis of chronic lumbar disc disease and meet eligibility criteria will be enrolled. Chronic lumbar disc disease is defined as back and/or radicular pain with degeneration of the disc confirmed by patient history, physical examination, and radiographic measures such as computed tomography (CT), magnetic resonance imaging (MRI), plain film, myelography, discography, or other acceptable means.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This is a double-blind, controlled, randomized study with blinded assessments using a single dose. Subjects that have a current diagnosis of chronic lumbar disc disease and meet eligibility criteria will be enrolled. Chronic lumbar disc disease is defined as back and/or radicular pain with degeneration of the disc confirmed by patient history, physical examination, and radiographic measures such as computed tomography (CT), magnetic resonance imaging (MRI), plain film, myelography, discography, or other acceptable means.

Subjects randomized to active treatment will undergo bone marrow harvest for processing into BRTX- 100 for intradiscal injection. Subjects randomized to control will also undergo a bone marrow and blood harvest but only undergo a sham intradiscal injection procedure. Subjects will return to the study site for a visit at Week 2, Week 12, Week 26, Week 52 and Week 104/Early Termination.

The trial will have a Safety Run-In component that will insert a 3+3 design for the initial subjects dosed with BRTX-100 at 40 × 10^6 cells. Specifically, the randomization scheme will be briefly shifted from the overall trial 2:1 randomization to an initial 3:1 allotment of intradiscal BRTX-100 versus control.

As such, four subjects will initially be randomized and administered their agents. There will be a 14-day safety follow-up period that must elapse between dosing of each of the first four (4) subjects. Dosing of each subsequent subject in the Safety Run-In component cannot occur until the independent Medical Monitor (MM) reviews the previously dosed subject's blinded data, including but not limited to physical examination findings, laboratory values and reported adverse events (AEs) and serious adverse events (SAEs), at the completion of the 14-day visit and documents the findings. If no potential dose-limiting toxicity (DLT) is noted by the MM, the MM will approve the dosing of the next subject. If a potential DLT is noted by the MM, the MM will request that an ad hoc Data Safety Monitoring Board (DSMB) review of unblinded data occur per DSMB Charter before the next subject is dosed.

Study Type

Interventional

Enrollment (Estimated)

99

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35235
        • Withdrawn
        • Alabama Clinical Therapeutics, LLC
    • California
      • Santa Monica, California, United States, 90403
      • Walnut Creek, California, United States, 94598
        • Recruiting
        • Boomerang Healthcare
        • Principal Investigator:
          • Kasra Amirdelfan, MD
        • Contact:
        • Contact:
    • Colorado
    • Florida
      • Fort Lauderdale, Florida, United States, 33306
        • Withdrawn
        • Cantor Spine Institute
      • Jacksonville, Florida, United States, 32257
      • St. Petersburg, Florida, United States, 33709
      • Tampa, Florida, United States, 33603
      • Tampa, Florida, United States, 33614
        • Recruiting
        • Florida Pain Relief Center
        • Contact:
      • Winter Park, Florida, United States, 32789
    • New York
      • New York, New York, United States, 10022
    • North Carolina
      • Winston-Salem, North Carolina, United States, 27103
        • Recruiting
        • The Center of Clinical Research, LLC
        • Contact:
        • Contact:
    • Ohio
      • Cleveland, Ohio, United States, 44195
        • Recruiting
        • Cleveland Clinic
        • Contact:
    • Oklahoma
      • Edmond, Oklahoma, United States, 73013
        • Withdrawn
        • Clinical Investigations LLC
    • South Carolina
      • North Charleston, South Carolina, United States, 29406,
        • Withdrawn
        • Coastal Carolina Research Center
    • Texas
    • Virginia
      • Richmond, Virginia, United States, 23235

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Subject Inclusion Criteria:

A subject is eligible for inclusion if all the following criteria are met:

  1. A high index of suspicion for discogenic pain, (i.e., painful degenerative disc(s) with or without protrusions less than or equal to 5 mm)

    1. Chronic Lower Back Pain for at least 6 months
    2. Pain commonly provoked by prolonged sitting, forward bending, lifting, twisting, coughing, sneezing, or Valsalva maneuvers
    3. Failure of at least 6 months of conservative back pain care (can include any or all of the following: rest, anti-inflammatory medication, analgesics, narcotics, epidural injections or selective nerve root injections at the target level, facet joint injections, muscle relaxers, massage, acupuncture, chiropractic care)
    4. Failure of supervised therapy (such as physical therapy)
    5. Screening of ≥ 40 mm and ≤ 80 mm on low back pain visual analog scales (VAS) (average pain in the last week)
    6. Screening Oswestry Disability Index (ODI) score ≥ 30 and < 90 on a 100-point scale
    7. No localized and significant pain below beltline (i.e., potential sacroiliac joint pain) without lumbar pain component
    8. Thigh or Leg pain, if present, is non prevailing and of nonradicular origin, i.e., not due to stimulation of nerve roots or dorsal root ganglion of a spinal nerve by compressive forces
    9. Diagnostic medial branch block or facet joint injection (bilateral unless the symptoms are purely unilateral in nature) in the last 12 months prior to the informed consent date indicates no prevailing facet joint involvement

  2. Has degenerative disc disease (DDD) as defined by the following:

    1. Changes from normal disc morphology of the affected disc as defined by radiographic evaluation
    2. Modified Pfirrmann score of 2 to 7 on MRI, may contain a contained protrusion and/or annular tear on MRI
    3. Modified Pfirrmann score of 1 must contain a contained protrusion and/or annular tear on MRI
    4. Modic Grade I or II changes or no change on MRI
    5. Maintained intervertebral disc heights of at least 50% on MRI.
    6. Discography, if not performed within the last 6 months prior to informed consent date, has to be performed if more than one degenerative disc is identified by MRI, and the symptomatic disc cannot be otherwise reasonably determined
    7. If more than one degenerative disc is identified by MRI, no disc shall demonstrate greater degenerative change than the symptomatic disc or contain a protrusion greater than 5mm
  3. Aged ≥18 years of age at the time of consent
  4. Willing and able to provide written informed consent
  5. No evidence of contraindications to the procedure such as pregnancy, active infection, bleeding disorder, or metastatic cancer

Subject Exclusion Criteria:

A subject is not eligible to participate if any of the following criteria are met:

  1. Spinal Deformity (Scoliosis greater than or equal to 20 degrees, spondylolysis, clinically or radiographically significant retrolisthesis or spondylolisthesis) detected on MRI or plain film radiographic assessment
  2. Disc extrusions, sequestered fragments, facet cysts, or greater than moderate spinal stenosis on MRI.
  3. Presence of a Grade V annular fissure observed within the index disc level during discography in a subject for whom provocation discography has been performed
  4. Intervertebral disc with radiographic evidence of Modified Pfirrmann Grade 8 or greater
  5. Any bleeding disorder, intrinsic or extrinsic
  6. Required anticoagulation (with either antiplatelet agents or antithrombotics) that cannot be interrupted for harvest and injection procedures
  7. Platelet count less than or equal to 100,000
  8. International Normalized Ratio (INR) greater than or equal to 1.5
  9. Extreme obesity, as defined by NIH Clinical Guidelines Body Mass Index (BMI greater than or equal to 40)
  10. Clinically relevant instability on flexion-extension as determined by the investigator by overlaying films (flexion & extension films)
  11. Has undergone any previous lumbosacral spine surgery (e.g. discectomy, laminectomy, foraminotomy, fusion, intradiscal electrothermal therapy, intradiscal radiofrequency thermocoagulation.), ablation of lumbar basiverterbral nerve or therapeutic percutaneous disc intervention
  12. Have any acute or chronic lumbosacral spine fracture
  13. Have a history of lumbosacral epidural steroid injections within 1 month prior to informed consent date.
  14. Planned/expected use of systemic nonsteroidal anti-inflammatory drugs (NSAIDs) within 72 hours prior to study treatment.
  15. Have a known history of hypersensitivity or anaphylactic reaction to dimethyl sulfoxide (DMSO)
  16. Active significant non lumbosacral spinal orthopedic pain generators including, not limited to arthritic hip and/or knee, cervical disc disease
  17. More widespread and ill-defined myofascial pain
  18. Have had treatment with any cellular or biological investigational therapy or device within 6 months of informed consent date and/or plans to participate in any other autologous or allogeneic stem cell/progenitor cell therapy trial during the 2 year follow-up period
  19. Have been a recipient of any lumbosacral intervertebral disc injection for therapeutic purposes
  20. Are transient or has been treated in the last 6 months before enrollment for alcohol and/or drug abuse in an inpatient substance abuse program
  21. Apparent ongoing and poorly controlled psychological or somatic disease that may impact treatment outcomes
  22. Social, familial, or geographical hindrances to compliance with the study protocol or the informed consent process
  23. Known autoimmune disease with primary impact on the musculoskeletal and/or neurological systems (e.g., systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, myasthenia gravis, polymyositis/dermatomyositis, Guillain-Barre syndrome, autoimmune vasculitis)
  24. Required chronic immunosuppression
  25. Positive hepatitis C virus (HCV) antibody test
  26. Positive human immunodeficiency virus (HIV) Antigen/Antibody (Ag/Ab) Combo test
  27. Pregnant or lactating women

  28. Women of childbearing potential not protected by a highly effective method of birth control.

    Highly effective methods of contraception [defined as those, alone or in combination, that result in a low (<1%) failure rate] include, but are not limited to, combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation (either oral, intravaginal, transdermal or injectable), progestogen-only hormonal contraception associated with inhibition of ovulation (either oral, injectable or implantable), intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence, or a double-barrier method (i.e., male condom combined with diaphragm with spermicide). The investigator is responsible for review of medical history, contraception history, menstrual history and recent sexual activity to decrease the risk of including a woman with an undetected early pregnancy. Additionally, the investigator is responsible for determining if, in the investigator's judgment, a woman's planned contraceptive method (including an assessment of her reliability for consistent use of this method) meets the protocol requirement of "highly effective."

  29. Hematology and chemistry values including, but not limited to:

    1. Total bilirubin level 1.5 times institutional upper limit of normal (ULN)
    2. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 2 x ULN
    3. Absolute neutrophil count (ANC) < 1000/mm3
    4. Hemoglobin less than or equal to 10 g/dL
    5. Creatinine clearance use calculated clearance (Cockcroft-Gault equation) of less than or equal to 50 mL/min
    6. Other labs deemed clinically significant which, in the opinion of the investigator, might influence the subject's health or safety during the trial.
  30. Have any other active medical conditions, medical or psychiatric illness which, in the opinion of the Investigator, would preclude adequate evaluation of the safety and efficacy of the study or put the participant at risk
  31. Inability to comply with the requirements of the study protocol
  32. Actively on workers compensation or no-fault case for this complaint or any other active case or litigation pertaining to their lumbosacral pain.
  33. History of drug or alcohol abuse or documented history of noncompliance with controlled substances that, in the investigator's opinion, could interfere with adequate evaluation of the study drug's safety or efficacy or otherwise make the subject unsuitable for the study.
  34. History of regular, long term, daily opioid drug use (greater than or equal to 30 MME)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Active Treatment- BRTX-100
BRTX-100 consists of a population of hypoxic-cultured bone marrow mononuclear cells highly enriched in mesenchymal stem cells from autologous bone marrow with autologous platelet lysate.
Biological: BRTX-100
Hypoxic cultured mesenchymal stem cells (MSCs) from autologous bone marrow with autologous platelet lysate.
Sham Comparator: Sham

Isotonic saline will be used as a control (sham) in this study. Drug: saline (0.9% sodium chloride).

Please note this will be a sham procedure. This isotonic saline will not be injected intradiscally.
Drug: Saline
Sodium Chloride (0.9%) intravenous infusion preparation is a sterile and non-pyrogenic solution

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Primary Safety Measures
Time Frame: Baseline through Week 104 / Early Termination

Report of adverse events (AEs), clinical review and questionnaires for pain, disability and quality of life at Baseline through Week 104/ Early Termination

  • Vital Signs
  • Physical Examination
  • Laboratory Evaluation (hematology and chemistry)
  • Clinical review of MRI changes from Baseline to Week 104 (MRI density measurements in T2 weighted images performed at Baseline, Week 52 and Week 104 with predetermined MRI rating scores)
Baseline through Week 104 / Early Termination
Primary Efficacy Measures
Time Frame: Baseline through Week 52
  • VAS for Pain Assessment
  • ODI for Functional Assessment

Primary Efficacy Endpoint:

Clinical response, defined as at least a 30% decrease in pain as measured on the VAS scale and at least a 30% increase in function based on the ODI at Week 52 as compared to baseline.
Baseline through Week 52

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

BioRestorative Therapies

Investigators

  • Study Chair: Jason Lipitz, MD, BioRestorative Therapies

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 30, 2022

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2027

Study Registration Dates

First Submitted

July 31, 2019

First Submitted That Met QC Criteria

July 31, 2019

First Posted (Actual)

August 2, 2019

Study Record Updates

Last Update Posted (Estimated)

August 26, 2025

Last Update Submitted That Met QC Criteria

August 20, 2025

Last Verified

August 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CLDD-001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lumbar Disc Disease

Clinical Trials on BRTX-100

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe